RHIZEN-PHARMACEUTICALS
9.2.2021 05:47:10 CET | Business Wire | Press release
Rhizen Pharmaceuticals, a clinical-stage oncology-focused biopharmaceutical company, today announced that its novel next generation PI3K-delta inhibitor, Umbralisib, which was licensed to TG Therapeutics (NASDAQ:TGTX), has secured US FDA accelerated approval for the treatment of:
- adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20 based regimen, and
- adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.
Accelerated approval was granted for these indications, under a priority review (MZL), based on the results of the Phase 2 UNITY-NHL Trial (NCT02793583); in MZL, an ORR of 49% with 16% complete responses and in FL an ORR of 43% with 3% complete responses were achieved, respectively. Umbralisib was earlier granted Breakthrough Therapy Designation (BTD) for the treatment of MZL and orphan drug designation (ODD) for the treatment of MZL and FL.
Umbralisib is a novel, next generation, oral, once daily, inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1 (CK1) epsilon and was discovered by Rhizen Pharma and subsequently licensed to TG Therapeutics (NASDAQ:TGTX) at an IND stage (TGR 1202) in 2012. In 2014, both parties entered into a licensing agreement as a part of which TGTX obtained worldwide rights and Rhizen has retained commercialization rights for India while also being the manufacturing and supply partner for Umbralisib.
Swaroop Vakkalanka, President & CEO of Rhizen Pharmaceuticals said: “Umbralisib’s approval offers MZL & FL patients a new treatment option and is a huge validation of Rhizen’s drug discovery & development capabilities. This is a momentous occasion in Rhizen’s journey as a successful biotech that speaks of the true ability of our team to discover & develop safe and effective therapies that can last the rigors of drug development. Further, we are keen to bring Umbralisib to Indian patients and we plan to initiate activities towards registration and approval there soon.”
Pranav Amin, Chairman, Rhizen Pharmaceuticals & Managing Director of Alembic Pharmaceuticals Ltd said: “We are extremely proud of this historic milestone for Rhizen, and of the fact that Umbralisib is the first NCE discovered by Indian scientists to secure a US FDA approval. We are committed to working together with TG Therapeutics and Rhizen Pharma to ensure uninterrupted supply of UKONIQ™. Umbralisib is the first discovery asset to come out of Rhizen’s R&D efforts and this approval heralds the promise of the rest of Rhizen’s deep pipeline and continuing efforts.”
About Umbralisib:
Umbralisib is the first and only oral inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1 (CK1) epsilon. PI3K-delta is known to play an important role in supporting cell proliferation and survival, cell differentiation, intercellular trafficking and immunity and is expressed in both normal and malignant B-cells. CK1-epsilon is a regulator of oncoprotein translation and has been implicated in the pathogenesis of cancer cells, including lymphoid malignancies. Umbralisib is indicated for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen and for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy. These indications are approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. More information on Umbralisib or UKONIQ™ can be found at https://www.tgtherapeutics.com/prescribing-information/uspi-ukon.pdf .
About Alembic Pharmaceuticals Ltd:
Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA. Alembic is one of the leaders in branded generics in India. Alembic’s products that are marketed through a marketing team of over 5000 are well recognized by doctors and patients.
Information about Alembic can be found at http://www.alembicpharmaceuticals.com/ .
(Reuters: ALEM.NS) (Bloomberg: ALPM) (NSE: APLL TD) (BSE: 533573)
About Rhizen Pharmaceuticals A.G.:
Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel onco-therapeutics. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways. Rhizen is headquartered in Basel, Switzerland. For additional information, please visit www.rhizen.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210208005742/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Uptime Institute Partners with the Governorate of Nineveh to Advance Iraq’s Digital Infrastructure at the U.S.-Iraq Business Summit27.7.2026 09:02:00 CEST | Press release
A landmark partnership signed during Prime Minister Ali Al-Zaidi’s historic U.S. delegation positions Iraq for a new era of resilient, world-class digital infrastructure Uptime Institute today announced a landmark strategic partnership with the Governorate of Nineveh, signed at the U.S. Chamber of Commerce U.S.-Iraq Business Summit to accelerate the region’s digital transformation and advance Iraq’s national digital agenda. The agreement was signed on July 17, 2026, during the official U.S. visit of Iraqi Prime Minister Ali Al-Zaidi. Uptime Institute participated as part of the official delegation at a historic summit that yielded more than 50 agreements valued at over USD $60 billion, signaling a powerful new era of economic cooperation, investment, and technological innovation between the United States and Iraq. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260727139625/en/ Signing of landmark strategic partnership with A
Objectway Expands Into Capital Markets With Its Project to Acquire French Specialist SLIB, Pushing Forward Its Pan-European Growth Strategy27.7.2026 08:45:00 CEST | Press release
Strong complementary offering and expertise create new opportunities for strengthening strategic presence in France and broadening end-to-end proposition across key European markets.Key takeaways With this transaction, Objectway will extend its direct presence in France, adding another leading financial centre to its current footprint in major European hubs such as Italy, Germany, Switzerland, Benelux and the UK. Objectway will expand its offering across the investment services value chain, adding capital markets capabilities to its existing proposition for wealth management, private banking and asset management. SLIB will also broaden Objectway's client base with major European asset servicers, broker-dealers and banks, alongside strengthening Objectway's long-standing relationships with shared clients such as BNP Paribas. Objectway, the pan-European wealthtech solution partner for banking, wealth and asset management firms, today announced that it has entered into exclusive negotiati
Ant Group Unveils Ling-3.0-Flash Delivering Top-Tier Performance at a Fraction of the Parameter Scale27.7.2026 08:00:00 CEST | Press release
Ant Group today announced the release of Ling-3.0-Flash, a next-generation native hybrid-reasoning foundational model engineered specifically for production-grade AI agent workflows. Designed to deliver rapid response capabilities, it serves as a high-speed execution node that offers a superior balance of intelligence density and cost-efficiency. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260726584441/en/ Ling-3.0-Flash delivers strong performance across multiple core benchmarks. Featuring 124B total parameters with only 5.1B active parameters per token, Ling-3.0-Flash achieves remarkable performance despite its streamlined footprint. It matches or surpasses industry-leading models with two to three times its parameter scale across core benchmarks, including foundational reasoning, instruction following, and long-context processing. Architectural Innovation for Efficiency Ling-3.0-Flash moves away from the traditional ap
SES Statement On FCC Upper C-band Auction Decision27.7.2026 07:30:00 CEST | Press release
SES, a leading space solutions company, issued the following statement following the U.S. Federal Communications Commission approval of the Upper C-band Report & Order that makes 160 megahertz of the Upper C-band available in the contiguous United States for flexible-use, next-generation terrestrial wireless services via a system of competitive bidding. The required auction of the Upper C-band will be completed no later than July 2027, with spectrum clearing deadlines in 2030 and 2031. Gross incentive payments of approximately $5.6 billion to SES are contingent on spectrum clearing within the transition deadlines. The Order also confirms reimbursement of reasonable and necessary Upper C-band transition costs as approved by the clearinghouse. SES CEO Adel Al-Saleh Commented: “We commend Chairman Carr and the FCC staff for their diligence, speed, and hard work. We remain fully committed to working cooperatively with the FCC and all stakeholders as the process progresses. We are pleased t
LTM and Cognition Partner to Reduce Cyber Risk in Financial Services with Devin27.7.2026 07:00:00 CEST | Press release
LTM, the Business Creativity partner to the world's largest enterprises, today announced a strategic partnership with Cognition, the AI lab behind the software engineering agent Devin. As a part of this partnership, LTM has onboarded Devin, Cognition’s Autonomous AI Engineer as part of BlueVerseTM RightLogic. LTM BlueVerse RightLogic, is a cybersecurity assessment and risk assurance framework designed to help enterprises identify, assess and remediate cyber exposure as they accelerate AI adoption. Together, the companies will prioritize financial services sector, where Devin is most proven and where LTM brings deep institutional expertise. As AI adoption accelerates, many financial institutions are facing a widening gap between innovation and cyber risk visibility. BlueVerse RightLogic closes this gap by autonomously identifying, prioritizing and remediating vulnerabilities across banking infrastructure, applications, AI systems, software supply chains and governance—including exploits
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom